Endoglin-Mediated Suppression of Prostate Cancer Invasion Is Regulated by Activin and Bone Morphogenetic Protein Type II Receptors

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Breen, Michael J ^a   Moran, Diarmuid M ^a,d   Liu, Wenzhe ^a   Huang, Xiaoke ^a   Vary, Calvin P H ^c   Bergan, Raymond C ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Maine Medical Center Research Institute   (United States)

^d IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; ACTIVIN A; ACTIVIN RECEPTOR 2; ACTIVIN RECEPTOR LIKE KINASE 1; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; ENDOGLIN; SMAD1 PROTEIN; SMAD5 PROTEIN; SMAD8 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MORTALITY; CELL INVASION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LIGAND BINDING; PHENOTYPE; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR INVASION; WESTERN BLOTTING;

ACTIVIN RECEPTORS, TYPE II; ACTIVINS; ANTIGENS, CD; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE II; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SMAD1 PROTEIN;

EID: 84881506626     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072407     Document Type: Article

References (82)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA: A Cancer Journal for Clinicians 60: 277-300.
2. Zelefsky MJ, Eastham JA, Sartor OA, Kantoff P (2008) Cancer of the Prostate. Cancer: Principles & Practice of Oncology. 8th ed ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. pp. 1392-1452.
3. Fidler IJ, (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews Cancer 3: 453-458.
4. Massagué J, (2008) TGFbeta in Cancer. Cell 134: 215-230.
5. Pavese JM, Farmer RL, Bergan RC, (2010) Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Reviews 29: 465-482.
6. Heldin C-H (2008) TGF-β Signaling from Receptors to Smads. The TGF-β Family. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press. pp. 259-286.
7. Cheifetz S, Bellón T, Calés C, Vera S, Bernabeu C, et al. (1992) Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells. The Journal of Biological Chemistry 267: 19027-19030.
8. Lastres P, Letamendía A, Zhang H, Rius C, Almendro N, et al. (1996) Endoglin modulates cellular responses to TGF-beta 1. The Journal of Cell Biology 133: 1109-1121.
9. Letamendía A, Lastres P, Botella LM, Raab U, Langa C, et al. (1998) Role of endoglin in cellular responses to transforming growth factor-beta. A comparative study with betaglycan. The Journal of Biological Chemistry 273: 33011-33019.
10. Goumans M-J, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, et al. (2002) Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. The EMBO Journal 21: 1743-1753.
11. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, et al. (2003) Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Molecular Cell 12: 817-828.
12. Blanco FJ, Santibanez JF, Guerrero-Esteo M, Langa C, Vary CPH, et al. (2005) Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. Journal of Cellular Physiology 204: 574-584.
13. Scherner O, Meurer SK, Tihaa L, Gressner AM, Weiskirchen R, (2007) Endoglin differentially modulates antagonistic transforming growth factor-beta1 and BMP-7 signaling. The Journal of Biological Chemistry 282: 13934-13943.
14. Craft CS, Romero D, Vary CPH, Bergan RC, (2007) Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. Oncogene 26: 7240-7250.
15. Conley BA, Koleva R, Smith JD, Kacer D, Zhang D, et al. (2004) Endoglin controls cell migration and composition of focal adhesions: function of the cytosolic domain. The Journal of Biological Chemistry 279: 27440-27449.
16. Sanz-Rodriguez F, Guerrero-Esteo M, Botella L-M, Banville D, Vary CPH, et al. (2004) Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the Lim family of proteins. The Journal of Biological Chemistry 279: 32858-32868.
17. Muenzner P, Rohde M, Kneitz S, Hauck CR, (2005) CEACAM engagement by human pathogens enhances cell adhesion and counteracts bacteria-induced detachment of epithelial cells. The Journal of Cell Biology 170: 825-836.
18. Muenzner P, Bachmann V, Zimmermann W, Hentschel J, Hauck CR, (2010) Human-restricted bacterial pathogens block shedding of epithelial cells by stimulating integrin activation. Science (New York, NY) 329: 1197-1201.
19. Pardali E, van der Schaft DWJ, Wiercinska E, Gorter A, Hogendoorn PCW, et al. (2011) Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene 30: 334-345.
20. Rivera LB, Brekken RA, (2011) SPARC promotes pericyte recruitment via inhibition of endoglin-dependent TGF-β1 activity. The Journal of Cell Biology 193: 1305-1319.
21. Tian H, Mythreye K, Golzio C, Katsanis N, Blobe GC, (2012) Endoglin mediates fibronectin/α5β1 integrin and TGF-β pathway crosstalk in endothelial cells. The EMBO journal 31: 3885-3900.
22. Santibanez JF, Pérez-Gómez E, Fernandez-L A, Garrido-Martin EM, Carnero A, et al. (2010) The TGF-beta co-receptor endoglin modulates the expression and transforming potential of H-Ras. Carcinogenesis 31: 2145-2154.
23. Bernabeu C, Lopez-Novoa JM, Quintanilla M, (2009) The emerging role of TGF-beta superfamily coreceptors in cancer. Biochimica Et Biophysica Acta 1792: 954-973.
24. Pérez-Gómez E, Del Castillo G, Juan Francisco S, López-Novoa JM, Bernabéu C, et al. (2010) The role of the TGF-β coreceptor endoglin in cancer. TheScientificWorldJournal 10: 2367-2384.
25. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, et al. (1994) Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nature Genetics 8: 345-351.
26. Lebrin F, Deckers M, Bertolino P, Ten Dijke P, (2005) TGF-beta receptor function in the endothelium. Cardiovascular Research 65: 599-608.
27. Wikström P, Lissbrant IF, Stattin P, Egevad L, Bergh A, (2002) Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. The Prostate 51: 268-275.
28. El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, et al. (2007) Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. American Journal of Clinical Pathology 127: 572-579.
29. Romero D, O'Neill C, Terzic A, Contois L, Young K, et al. (2011) Endoglin regulates cancer-stromal cell interactions in prostate tumors. Cancer Res 71: 3482-3493.
30. Kassouf W, Ismail HRA, Aprikian AG, Chevalier S, (2004) Whole-mount prostate sections reveal differential endoglin expression in stromal, epithelial, and endothelial cells with the development of prostate cancer. Prostate Cancer and Prostatic Diseases 7: 105-110.
31. Liu Y, Jovanovic B, Pins M, Lee C, Bergan RC, (2002) Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion. Oncogene 21: 8272-8281.
32. Craft CS, Xu L, Romero D, Vary CPH, Bergan RC, (2008) Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells. Molecular Pharmacology 73: 235-242.
33. Lakshman M, Huang X, Ananthanarayanan V, Jovanovic B, Liu Y, et al. (2011) Endoglin suppresses human prostate cancer metastasis. Clinical & Experimental Metastasis 28: 39-53.
34. Lakshman M, Xu L, Ananthanarayanan V, Cooper J, Takimoto CH, et al. (2008) Dietary genistein inhibits metastasis of human prostate cancer in mice. Cancer Research 68: 2024-2032.
35. ATCC (2007) Cell Line Verification Test Recommendations. ATCC Technical Bulletin No. 8: 1-3.
36. Xu L, Ding Y, Catalona WJ, Yang XJ, Anderson WF, et al. (2009) MEK4 function, genistein treatment, and invasion of human prostate cancer cells. Journal of the National Cancer Institute 101: 1141-1155.
37. Attisano L, Wrana JL, Cheifetz S, Massagué J, (1992) Novel activin receptors: distinct genes and alternative mRNA splicing generate a repertoire of serine/threonine kinase receptors. Cell 68: 97-108.
38. Gray PC, Greenwald J, Blount AL, Kunitake KS, Donaldson CJ, et al. (2000) Identification of a binding site on the type II activin receptor for activin and inhibin. The Journal of biological chemistry 275: 3206-3212.
39. Lee-Hoeflich ST, Causing CG, Podkowa M, Zhao X, Wrana JL, et al. (2004) Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP-dependent dendritogenesis. The EMBO Journal 23: 4792-4801.
40. Korchynskyi O, ten Dijke P, (2002) Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. The Journal of Biological Chemistry 277: 4883-4891.
41. Huang X, Chen S, Xu L, Liu Y, Deb DK, et al. (2005) Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Research 65: 3470-3478.
42. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
43. Hayes SA, Huang X, Kambhampati S, Platanias LC, Bergan RC, (2003) p38 MAP kinase modulates Smad-dependent changes in human prostate cell adhesion. Oncogene 22: 4841-4850.
44. Barbara NP, Wrana JL, Letarte M, (1999) Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. The Journal of Biological Chemistry 274: 584-594.
45. Craft CS, Xu L, Romero D, Vary CP, Bergan RC, (2008) Genistein induces phenotypic reversion of endoglin deficiency in human prostate cancer cells. Mol Pharmacol 73: 235-242.
46. Kim IY, Lee D-H, Lee DK, Ahn H-J, Kim MM, et al. (2004) Loss of expression of bone morphogenetic protein receptor type II in human prostate cancer cells. Oncogene 23: 7651-7659.
47. Spanjol J, Djordjević G, Markić D, Klarić M, Fuckar D, et al. (2010) Role of bone morphogenetic proteins in human prostate cancer pathogenesis and development of bone metastases: immunohistochemical study. Collegium Antropologicum 34Suppl 2: 119-125.
48. Kawabata M, Imamura T, Miyazono K, (1998) Signal transduction by bone morphogenetic proteins. Cytokine & growth factor reviews 9: 49-61.
49. Yu PB, Beppu H, Kawai N, Li E, Bloch KD, (2005) Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells. The Journal of Biological Chemistry 280: 24443-24450.
50. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, Bernabeu C, (2002) Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. The Journal of Biological Chemistry 277: 29197-29209.
51. Perron JC, Dodd J (2009) ActRIIA and BMPRII Type II BMP Receptor Subunits Selectively Required for Smad4-Independent BMP7-Evoked Chemotaxis. PLoS ONE 4.
52. Wong WKP, Knowles JA, Morse JH, (2005) Bone Morphogenetic Protein Receptor Type II C-Terminus Interacts with c-Src: Implication for a Role in Pulmonary Arterial Hypertension. Am J Respir Cell Mol Biol 33: 438-446.
53. West J, Harral J, Lane K, Deng Y, Ickes B, et al. (2008) Mice expressing BMPR2R899X transgene in smooth muscle develop pulmonary vascular lesions. American Journal of Physiology Lung Cellular and Molecular Physiology 295: L744-755-L744-755.
54. West J, Fagan K, Steudel W, Fouty B, Lane K, et al. (2004) Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circulation research 94: 1109-1114.
55. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, et al. (2004) BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. American Journal of Physiology- Lung Cellular and Molecular Physiology 287: L1241-L1247.
56. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, et al. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. American Journal of Human Genetics 67: 737-744.
57. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, (2000) Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nature Genetics 26: 81-84.
58. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, et al. (2000) Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. Journal of Medical Genetics 37: 741-745.
59. Rudarakanchana N, Flanagan JA, Chen H, Upton PD, Machado R, et al. (2002) Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Human Molecular Genetics 11: 1517-1525.
60. Nishihara A, Watabe T, Imamura T, Miyazono K, (2002) Functional heterogeneity of bone morphogenetic protein receptor-II mutants found in patients with primary pulmonary hypertension. Molecular Biology of the Cell 13: 3055-3063.
61. Chan MC, Nguyen PH, Davis BN, Ohoka N, Hayashi H, et al. (2007) A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor. Molecular and Cellular Biology 27: 5776-5789.
62. Schwappacher R, Weiske J, Heining E, Ezerski V, Marom B, et al. (2009) Novel crosstalk to BMP signalling: cGMP-dependent kinase I modulates BMP receptor and Smad activity. The EMBO Journal 28: 1537-1550.
63. Machado RD, Rudarakanchana N, Atkinson C, Flanagan JA, Harrison R, et al. (2003) Functional interaction between BMPR-II and Tctex-1, a light chain of Dynein, is isoform-specific and disrupted by mutations underlying primary pulmonary hypertension. Human Molecular Genetics 12: 3277-3286.
64. Foletta VC, Lim MA, Soosairajah J, Kelly AP, Stanley EG, et al. (2003) Direct signaling by the BMP type II receptor via the cytoskeletal regulator LIMK1. The Journal of Cell Biology 162: 1089-1098.
65. Neuman NA, Ma S, Schnitzler GR, Zhu Y, Lagna G, et al. (2009) The four-and-a-half LIM domain protein 2 regulates vascular smooth muscle phenotype and vascular tone. The Journal of Biological Chemistry 284: 13202-13212.
66. Meng Q, Lux A, Holloschi A, Li J, Hughes JMX, et al. (2006) Identification of Tctex2beta, a novel dynein light chain family member that interacts with different transforming growth factor-beta receptors. The Journal of Biological Chemistry 281: 37069-37080.
67. Sieber C, Kopf J, Hiepen C, Knaus P, (2009) Recent advances in BMP receptor signaling. Cytokine & Growth Factor Reviews 20: 343-355.
68. Katagiri T, Suda T, Miyazono K (2008) The Bone Morphogenic Proteins. The TGF-β Family. Cold Spring Harbor, N.Y: Cold Spring Harbor Laboratory Press. pp. 121-150.
69. David L, Mallet C, Mazerbourg S, Feige J-J, Bailly S, (2007) Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells. Blood 109: 1953-1961.
70. Yu PB, Deng DY, Beppu H, Hong CC, Lai C, et al. (2008) Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. The Journal of Biological Chemistry 283: 3877-3888.
71. Yang S, Zhong C, Frenkel B, Reddi AH, Roy-Burman P, (2005) Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells. Cancer Research 65: 5769-5777.
72. Feeley BT, Krenek L, Liu N, Hsu WK, Gamradt SC, et al. (2006) Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions. Bone 38: 154-166.
73. Grijelmo C, Rodrigue C, Svrcek M, Bruyneel E, Hendrix A, et al. (2007) Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cellular Signalling 19: 1722-1732.
74. Katsuno Y, Hanyu A, Kanda H, Ishikawa Y, Akiyama F, et al. (2008) Bone morphogenetic protein signaling enhances invasion and bone metastasis of breast cancer cells through Smad pathway. Oncogene 27: 6322-6333.
75. Darby S, Cross S, Brown N, Hamdy F, Robson C, (2008) BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype. The Journal of Pathology 214: 394-404.
76. Buijs JT, Rentsch CA, van der Horst G, van Overveld PGM, Wetterwald A, et al. (2007) BMP7, a Putative Regulator of Epithelial Homeostasis in the Human Prostate, Is a Potent Inhibitor of Prostate Cancer Bone Metastasis in Vivo. Am J Pathol 171: 1047-1057.
77. Ye L, Kynaston H, Jiang WG, (2008) Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Molecular Cancer Research: MCR 6: 1594-1606.
78. Ye L, Kynaston H, Jiang WG, (2009) Bone morphogenetic protein-10 suppresses the growth and aggressiveness of prostate cancer cells through a Smad independent pathway. The Journal of Urology 181: 2749-2759.
79. Owens P, Pickup MW, Novitskiy SV, Chytil A, Gorska AE, et al. (2012) Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proceedings of the National Academy of Sciences of the United States of America 109: 2814-2819.
80. Ye L, Bokobza S, Li J, Moazzam M, Chen J, et al. (2010) Bone morphogenetic protein-10 (BMP-10) inhibits aggressiveness of breast cancer cells and correlates with poor prognosis in breast cancer. Cancer Science 101: 2137-2144.
81. Romero D, O'Neill C, Terzic A, Contois L, Young K, et al. (2011) Endoglin regulates cancer-stromal cell interactions in prostate tumors. Cancer research 71: 3482-3493.
82. Romero D, Terzic A, Conley BA, Craft C, Jovanovic B, et al. (2009) Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration. Carcinogenesis.